Anticoagulant plus antiplatelet therapy for atrial fibrillation : Cost-utility of combination therapy with non-vitamin K oral anticoagulants vs. warfarin.

Bode, K; Hindricks, G; Ten Berg, J M; Whittaker, P

Bode, K; Hindricks, G; Ten Berg, J M; Whittaker, P.

Affiliation

Bode K; Department of Electrophysiology, Heart Centre Leipzig, University of Leipzig, Struempellstraße 39, 04289, Leipzig, Germany. kerstin.bode@medizin.uni-leipzig.de.
Hindricks G; Department of Health Policy, London School of Economics and Political Science, London, UK. kerstin.bode@medizin.uni-leipzig.de.
Ten Berg JM; Department of Electrophysiology, Heart Centre Leipzig, University of Leipzig, Struempellstraße 39, 04289, Leipzig, Germany.
Whittaker P; Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.

Herz ; 45(6): 564-571, 2020 Sep.

Article in En | MEDLINE | ID: mdl-30209519

Subject(s)

Atrial Fibrillation; Stroke; Administration, Oral; Anticoagulants/therapeutic use; Atrial Fibrillation/drug therapy; Humans; Platelet Aggregation Inhibitors/therapeutic use; Stroke/drug therapy; Stroke/prevention & control; Vitamin K; Warfarin/therapeutic use

Key words

Anticoagulation agents; Coronary artery disease; Costutility; Non-vitamin K antagonist; Platelet aggregation inhibitors; Warfarin

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Atrial Fibrillation / Stroke Type of study: Clinical_trials / Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Humans Language: En Journal: Herz Year: 2020 Document type: Article Affiliation country: Germany Country of publication: Germany

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google